Featuring presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Nemo enim ipsam voluptatem quia voluptas sit odit aut fugit!
Ut enim ad minima veniam, quis nostrum exercitationem ullam!